top of page
Search

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

Amit Roy

Following ASCO 24, we update our detailed analysis of the current phase late-stage ADC data from AZN/Daiichi’s TROPION Gilead’s EVOKE and MRK/SKB’s program in Lung Cancer and still find steep obstacles that may be too high to surmount...


CYTK BMY

Comments


Commenting has been turned off.
Focus Research
Recent Reseacrh
Archive
Search By Tags
Follow Us on:
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
  • LinkedIn Classic
  • Twitter Classic

Foveal LLP is authorised and regulated by the Financial Conduct Authority. Firm no: 646980

Registered in England and Wales, No: OC394934. Registered Office: One Fleet Place, London EC4M 7WS, UK

© Foveal LLP & Amit Roy Photography. All rights reserved. Foveal and the foveal logo are registered trademarks of Foveal LLP

bottom of page